Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 9/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.46 |
| ▸ | FBP1 | P09467 | 2/20 | 0.46 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31296648 | 0.84 | MEN1 (0.55) | POLBMAPTALDH1A1HPGDRAPGEF4 | |
| SCHEMBL31296647 | 0.84 | MEN1 (0.55) | POLBMAPTALDH1A1HPGDRAPGEF4 | |
| SCHEMBL6584815 | 0.84 | EGFR (0.63) | EGFRERBB2FBP1ERBB4 | |
| SCHEMBL26116957 | 0.84 | MEN1 (0.55) | POLBMAPTALDH1A1HPGDRAPGEF4 | |
| SCHEMBL7093309 | 0.83 | POLB (0.55) | POLBGAAMAPTALDH1A1RAPGEF4 | |
| SCHEMBL7572017 | 0.83 | POLB (0.55) | POLBGAAMAPTALDH1A1HPGD | |
| SCHEMBL10112748 | 0.82 | POLB (0.68) | POLBGAAMAPTALDH1A1RAPGEF4 | |
| SCHEMBL6549773 | 0.82 | POLB (0.68) | POLBGAAMAPTMEN1KMT2A | |
| SCHEMBL1891550 | 0.81 | EGFR (0.68) | EGFRERBB2 | |
| SCHEMBL7571748 | 0.80 | POLB (0.51) | POLBGAAMAPTALDH1A1RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117633-B1 | DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2002-09-18 | — | — | EP | disclosed |
| US-6413996-B2 | CHLORIDE CHANNEL BLOCKERS; FOR TREATMENT OF SICKLE CELL ANAEMIA, BRAIN OEDEMA FOLLOWING ISCHAEMIA OR TUMOURS, DIARRHOEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, BONE METASTASIZING CANCERS | NEUROSEARCH A/S (DK) | 2002-07-02 | — | — | US | disclosed |
| US-20010056092-A1 | Diaminocyclobutene-3,4-dione derivatives, their preparation and use | ANIONA APS (DK) | 2001-12-27 | — | — | US | disclosed |
| EP-1117633-A1 | DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020378-A1 | DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056092-A1 | Diaminocyclobutene-3,4-dione derivatives, their preparation and use | HCN4, CLIC1, KCNB1 | POLB 2087/4885GAA 3075/4885MAPT 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.